Search
Scorpion (centruroides) immune Fab2 antivenin (equine)
go.drugbank.com/drugs/DB13905ApprovedSevere scorpion stings may cause loss of muscle control and respiratory failure, warranting heavy sedation and hospitalization in an intensive care unit. … Envenomation by a scorpion sting can result in serious cardiovascular effects [A32483].
Human Umbilical Cord Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15726InvestigationalCurrently many companies are creating their own version of these stem cells, one of which is by Aspire, who are creating a version named ACT-20. … The cells are extracted by either the explant or the enzymatic digestion method, though neither method has been characterized as the ‘standard’ thus far.
Citrulline
go.drugbank.com/drugs/DB00155InvestigationalNutraceuticalIts name is derived from citrullus, the Latin word for watermelon, from which it was first isolated. … Citrulline is an amino acid. It is made from ornithine and carbamoyl phosphate in one of the central reactions in the urea cycle.
Cefamandole
go.drugbank.com/drugs/DB01326ApprovedWithdrawnCefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, cefamandole nafate. It is no longer marketed in the United States.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UsePatiromer
go.drugbank.com/drugs/DB09263ApprovedInvestigationalPatiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. … Patiromer sorbitex calcium is an amorphous, free-flowing powder that is composed of individual spherical beads.
Progabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated
Mobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawn[A238828] Mobocertinib appears to be an effective means of treating this otherwise treatment-resistant NSCLC, exerting an inhibitory effect on _EGFR_ exon 20 insertion mutant variants at concentrations … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsPF-04691502
go.drugbank.com/drugs/DB11974InvestigationalPF-04691502 has been used in trials studying the treatment of Cancer, Breast Neoplasms, Early Breast Cancer (Phase 2), and Advanced Breast Cancer (Phase 1b).
Enadenotucirev
go.drugbank.com/drugs/DB14873InvestigationalEnadenotucirev is under investigation in clinical trial NCT02636036 (Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors).
Uteroglobin
go.drugbank.com/drugs/DB14880InvestigationalUteroglobin is under investigation in clinical trial NCT01473264 (Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)).